Premium
In vivo studies of [ 125 I]iodobenzamide and [ 11 C]iodobenzamide: A ligand suitable for positron emission tomography and single photon emission tomography imaging of cerebral D 2 dopamine receptors
Author(s) -
Wong Dean F.,
Wilson Alan A.,
Chen Catherine,
Minkin Elynne,
Dannals Robert F.,
Ravert Hayden T.,
SanchezRoa Patricia,
Villemagne Victor,
Wagner Henry N.
Publication year - 1992
Publication title -
synapse
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.809
H-Index - 106
eISSN - 1098-2396
pISSN - 0887-4476
DOI - 10.1002/syn.890120309
Subject(s) - raclopride , in vivo , positron emission tomography , biodistribution , preclinical imaging , ligand (biochemistry) , chemistry , brain positron emission tomography , biophysics , dopamine receptor d2 , pharmacology , nuclear medicine , receptor , biology , biochemistry , medicine , microbiology and biotechnology
Abstract Iodobenzamide (IMB) labeled with either [ 11 C] or [ 125 I] was studied in mice and baboons. Pharmacological studies demonstrated an in vivo binding profile compatible with D 2 dopamine receptors. Mouse biodistribution studies with both [ 11 C]IMB and [ 125 I]IMB showed a similar brain distribution of radioactivity. Mouse [ 125 I]IMB studies with amphetamine and reserpine pretreatment suggested that IMB may be less susceptible to endogenous dopamine competition for D 2 receptor binding in vivo as compared to raclopride. Preliminary baboon studies showed haloperidol competition for IMB binding sites. © 1992 Wiley‐Liss, Inc.